mynth
04/2026

HERNIAMESH acquired by VITREX MEDICAL GROUP

ITALY Life Sciences / Medical Devices / Implants & Prosthetics REV 1m EUR - 100m EUR

Context

Vitrex Medical Group (VMG) has finalized the acquisition of a majority stake in Herniamesh, an operation designed to fundamentally accelerate the group's transformation into a global leader in surgical technology. The strategic rationale for this transaction centers on a "portfolio-synergy" play, merging the target's industry-leading technical operational depth in surgical meshes with the group’s extensive distribution network and established suture division (CHIRMAX). This fusion effectively creates a specialized powerhouse in the European medtech arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of soft tissue repair and urogynecological procedures.

HERNIAMESH, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

erniamesh s.r.l. operates as a premier technology-enabled organization dedicated to the engineering and fabrication of advanced surgical solutions for the treatment of hernias, female incontinence, and pelvic floor disorders. The entity’s business model is centered on a proprietary innovation framework, utilizing clinical know-how established by renowned surgical practitioners to develop specialized medical materials. Its value proposition is anchored in technical operational depth, providing a high-fidelity portfolio of surgical meshes and biological materials that facilitate minimally invasive procedures and improve patient outcomes. Strategically, the firm focuses on the deployment of standardized, high-quality "Made in Italy" devices across a global commercial network spanning North America, Asia, and Latin America. By maintaining a specialized focus on technical reliability and surgical precision, the organization ensures a vital role in the structural advancement of soft tissue repair standards.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2026
2025

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
DateAcquirerTargetCountrySector
06/2026BRIDGEPOINTOBAGI MEDICALUNITED STATESGenerics / Labs
05/2026STRYKERAMPLITUDE VASCULAR SYSTEMSUNITED STATESMedical Devices
04/2026UCBNEURONA THERAPEUTICSUNITED STATESR&D Biotech
04/2026OURY MEDICALCÉFIMÉCAFRANCEImplants & Prosthetics
04/2026ASTORGTHERMO FISHER MICROBIOLOGYUNITED STATESDiagnostic Equipment
04/2026RANTUM CAPITALTONTARRA MEDIZINTECHNIKGERMANYMedical Devices
04/2026DEVYSER DIAGNOSTICSCYBERGENESWEDENDiagnostic Equipment
04/2026Gilead SciencesArcellxUNITED STATESR&D Biotech
04/2026REVENIO GROUP CORPORATIONVISIONIX INTERNATIONALFRANCEDiagnostic Equipment
04/2026FINE FOODS & PHARMACEUTICALSSOFARITALYCDMO

REFERENCES

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HERNIAMESH by VITREX MEDICAL GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: herniamesh

Acquirer: vitrex medical group